PAVMED INC

PAVMNASDAQ

🏆 #4639 by market capUS Equity

$402.02▲ $28.26 (+7.03%)

Simulated price

🔔

Track PAVM

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 7.0%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$31M

Small Cap

📈Revenue Growth (YoY)

-89.0%

Declining

📊Gross Margin

-220.5%

Thin

💵FCF Margin

—

⚖️P/S Ratio

274.5x

Expensive

Otter Score

Fair

No chart data available for PAVM.

Trading Snapshot

Day Range: $398.42 – $409.90
52-Week Range: $3.70 – $28.44
Volume: $4.41B
Avg Volume: $4.98B
Shares Outstanding: 7.2M
Next Earnings: Dec 13, 2026

Fundamentals Snapshot

Annual Revenue: $71,000
Last Q Revenue: $33,000
P/E Ratio: —
P/S Ratio: 274.5x
EPS (TTM): $-9.80
Dividend Yield: —
Dilution (1yr): +107.2%

Why Investors Own PAVM

✓High-growth profile — revenue up +25.5% YoY with expanding US Equity exposure.
✓Healthy economics — 78% gross margin and 28% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PAVMED INC

PAVM

Financial Trends

Revenue

$71K▼ −97.6% YoY

Gross Margin

-354.9%▲ +249.3% YoY

Operating Income

−$22M▼ −51.0% YoY

Free Cash Flow

−$5.2B▲ +15389.9% YoY

Shares Outstanding

774K▲ +107.2% YoY

Net Cash

−$12M▲ +$19M YoY

StockOtter · stockotter.space

About PAVMED INC

PAVmed Inc. operates as a U.S.-based medical technology firm. Its principal commercialized products include CarpX, a percutaneous device designed to address carpal tunnel syndrome. Other key offerings are EsoCheck, an esophageal cell collection device vital for the early detection of esophageal adenocarcinoma and Barrett's Esophagus (BE), and EsoGuard, a specialized bisulfite-converted next-generation sequencing DNA assay. The company's extensive development pipeline further encompasses EsoCure, an esophageal ablation device intended to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; and NextFlo, a disposable infusion platform technology. Also in development are the Veris cancer healthcare platform, which features an intelligent vascular port for combined remote monitoring and data analytics, alongside Veris cardiac monitors. Additional innovations include NextVent single-use ventilators, FlexMO medical circulatory support cannulas, DisappEAR resorbable pediatric ear tubes, and Solys for noninvasive glucose monitoring. Established in 2014, the enterprise originally traded as PAXmed Inc. before rebranding to PAVmed Inc. in April 2015. Its corporate headquarters are located in New York, New York.

🦦